^
BIOMARKER:

KMT2D mutation

i
Other names: KMT2D, Lysine Methyltransferase 2D, Histone-Lysine N-Methyltransferase 2D, Myeloid/Lymphoid Or Mixed-Lineage Leukemia 2, Lysine (K)-Specific Methyltransferase 2D, Trinucleotide Repeat Containing 21, Lysine N-Methyltransferase 2D, ALL1-Related Protein, MLL2, MLL4, ALR, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein, Histone-Lysine N-Methyltransferase MLL2, Truncated Lysine Methyltransferase 2D, Kabuki Mental Retardation Syndrome, Kabuki Make-Up Syndrome, CAGL114, KABUK1, TNRC21, AAD10
Entrez ID:
Related biomarkers:
KMT2D mutation
SCCHN
durvalumab + CP-675206
Sensitive: B - Late Trials
KMT2D mutation
Follicular Lymphoma
R-CHOP
Resistant: C3 – Early Trials
KMT2D mutation
Diffuse Large B Cell Lymphoma
chidamide
Resistant: C3 – Early Trials
KMT2D mutation
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
KMT2D mutation
Marginal Zone Lymphoma
ibrutinib
Resistant: C3 – Early Trials
KMT2D mutation
CRC
Immunotherapy
Sensitive: C3 – Early Trials
KMT2D mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
KMT2D mutation
CRC
Immunotherapy
Sensitive: C3 – Early Trials
KMT2D mutation
Cervical Cancer
anlotinib + sintilimab
Sensitive: C3 – Early Trials
KMT2D mutation
CLL
decitabine
Sensitive: D – Preclinical
KMT2D mutation
CLL
chidamide
Sensitive: D – Preclinical
KMT2D mutation
CLL
ibrutinib + chidamide
Sensitive: D – Preclinical
KMT2D mutation
CLL
ibrutinib + decitabine
Sensitive: D – Preclinical